Exchange: NASDAQ·Updated 04:36 PM EDT
TNDM logo

TNDMTandem Diabetes Care Inc

$15.01
$0.61
(4.23%)
Today
Closed $15.02
$0.01
(0.07%)
After Hours
EarningsAug 5
Mkt Cap$987.5M
Vol2.21M
News
all
press releases
NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
More News
News Placeholder
Wall Street Analysts See a 56.2% Upside in Tandem Diabetes Care (TNDM): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Tandem Diabetes Care (TNDM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
News Placeholder
Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of CE mark for expanded indications of its automated insulin delivery (AID) systems in Europe. The t:slim X2 and Tandem Mobi insulin delivery systems running Control-IQ...
Business Wire
News Placeholder
Zacks.com featured highlights include Tandem, Dell and CNO Financial
Tandem, Dell and CNO Financial have been highlighted in this Screen of The Week article.
Zacks
News Placeholder
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now
TNDM's pay-as-you-go shift, international expansion and strong liquidity support growth, while macro and reimbursement risks remain.
Zacks
News Placeholder
3 Stocks to Invest in as Broker Rating Upgrades Signal Upside
Broker upgrades flag upside in Tandem, Dell and CNO Financial as earnings forecasts jump and analysts lift ratings over the past four weeks.
Zacks
News Placeholder
Tandem Diabetes Valuation: Is 1.1x Sales a Buy?
TNDM trades near 1.1x forward sales as it shifts to pharmacy pay-as-you-go and expands Europe, with a $21 target tied to 1.3x sales.
Zacks
News Placeholder
TNDM Stock: What to Know About Tandem's 2026 Reset
Tandem Diabetes' Q1 beat, fatter margins and positive cash flow fuel its 2026 reset as it shifts more U.S. pump starts to pay-as-you-go pharmacy.
Zacks
News Placeholder
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
Zacks
News Placeholder
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up
Tandem Diabetes beats Q1 revenue and earnings estimates as gross margin expands, but shares decline 23.6% after the results announcement.
Zacks
<
1
2
...
>

Advertisement|Remove ads.